Cystocele Repair (Anterior Colporrhaphy) in India and UAE | Complete Patient Guide

ELIGIBLE CANDIDATES:

• Women with symptomatic cystocele POP-Q Stage II or higher causing voiding dysfunction, recurrent UTIs, pelvic pressure, or significant quality-of-life impairment

• Patients who have failed or declined conservative management (pelvic floor muscle training [Kegel exercises], pessary therapy, topical vaginal oestrogen)

• Women with concomitant stress urinary incontinence (SUI) confirmed on urodynamic testing, suitable for combined anterior colporrhaphy + mid-urethral sling

• Patients with post-void residual urine volume consistently >150 mL on bladder ultrasound

• Women with recurrent cystocele following prior native-tissue repair (candidates for mesh-augmented or robotic sacrocolpopexy)

• Medically optimised patients (BMI ideally <35 kg/m²; well-controlled diabetes HbA1c <8%; non-smokers or smoking-cessation ≥6 weeks pre-operatively)

REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• POP-Q clinical assessment by a urogynaecologist

• Multichannel urodynamic study (cystometry, uroflowmetry, pressure-flow study, leak-point pressure) — essential to differentiate stress, urgency, and mixed incontinence prior to planning concomitant procedures

• Pelvic floor MRI (dynamic defaecography MRI or conventional 3T MRI) — to map all compartment defects (anterior, middle, posterior) and paravaginal support

• Renal and bladder ultrasound (post-void residual, upper tract dilatation)

• Urine culture and sensitivity (mandatory; active UTI must be treated pre-operatively)

• Full blood count, coagulation screen (PT/APTT/INR), renal function, fasting glucose/HbA1c

• Electrocardiogram and anaesthetic fitness assessment (ASA classification; cardiopulmonary evaluation for patients >50 years or with comorbidities)

• Cervical smear (Pap test) — must be current (within 3 years) and negative

• Vaginal swab (to exclude bacterial vaginosis; reduces mesh infection risk)

CONTRAINDICATIONS:

• Active pelvic or vaginal infection (absolute; defer until treated)

• Pregnancy or planned future pregnancy in the near term (relative; surgery may destabilise pelvic anatomy further)

• Uncontrolled coagulopathy or anticoagulant therapy that cannot be safely bridged

• Unresected pelvic malignancy or prior pelvic radiation significantly compromising tissue vascularity

• Severe cardiorespiratory compromise precluding general or regional anaesthesia

• Uncorrected significant uterovaginal prolapse (vault or uterine) without concurrent apical support procedure — isolated anterior repair alone has higher recurrence rates

NATIVE-TISSUE ANTERIOR COLPORRHAPHY (STANDARD APPROACH): The foundational procedure involves a midline anterior vaginal incision, sharp dissection of the vaginal epithelium from the underlying pubocervical fascia, central plication of the fascial layer using delayed-absorbable sutures (polyglactin 910 or polydioxanone), and excision of redundant vaginal skin followed by multilayer closure. Site-specific defect repair (paravaginal repair) addresses discrete lateral or apical fascial tears rather than central plication alone, and is associated with lower recurrence rates in appropriately selected patients. The Kelly stitch or modified Kelly plication specifically reinforces the urethrovesical junction and is employed when mild stress incontinence is present without a full sling procedure.

MESH-AUGMENTED ANTERIOR REPAIR: For recurrent prolapse or poor-quality native tissue, lightweight macroporous polypropylene mesh (e.g., Gynecare Prolift Anterior, Restorelle DirectFix Anterior) or biological grafts (porcine small intestinal submucosa, cadaveric dermal allograft) are sutured over the plicated fascia to provide durable scaffolding. Surgeons at GAF partner hospitals strictly adhere to the FDA and NICE guidance thresholds for mesh use — limiting synthetic mesh to specific recurrent or high-risk cases after thorough informed consent regarding mesh-specific complications (erosion, dyspareunia, chronic pain). Biological grafts are preferred in younger, sexually active patients.

CONCOMITANT MID-URETHRAL SLING (TVT / TOT): When urodynamic stress incontinence coexists, a retropubic tension-free vaginal tape (TVT, Gynecare) or transobturator tape (TOT, inside-out or outside-in) is placed at the mid-urethra in the same operative session. Urodynamic-proven occult stress incontinence — unmasked only after prolapse reduction — is addressed prophylactically with a sling to prevent de novo SUI post-repair.

ROBOTIC-ASSISTED SACROCOLPOPEXY (ADVANCED / MINIMALLY INVASIVE): For high-grade cystocele with concurrent apical (vault or uterine) prolapse, robotic-assisted laparoscopic sacrocolpopexy using the da Vinci Xi or Si system offers the highest anatomical durability (recurrence rates <10% at 5 years) with minimal blood loss (<50 mL), superior 3D optics for precise dissection of the vesicovaginal and rectovaginal spaces, and wristed instrumentation enabling secure mesh fixation to the anterior longitudinal ligament at the sacral promontory. This approach is available at JCI/NABH-accredited centres in Mumbai, Chennai, and Hyderabad, and at DHA-licensed hospitals in Dubai.

LAPAROSCOPIC PARAVAGINAL REPAIR: Addresses lateral detachment of the pubocervical fascia from the arcus tendineus fasciae pelvis (ATFP — the 'white line'). Performed laparoscopically (2–4 ports) or robotically, it restores the lateral vaginal sulci and corrects the characteristic lateral-type cystocele missed by midline plication alone.

ANAESTHESIA OPTIONS: Spinal anaesthesia with sedation is the preferred modality at most partner centres, minimising opioid exposure, reducing post-operative nausea, and enabling same-day or next-morning ambulation. General anaesthesia with laryngeal mask airway (LMA) is used for combined or laparoscopic procedures. Enhanced Recovery After Surgery (ERAS) protocols — including pre-operative carbohydrate loading, intraoperative goal-directed fluid therapy, and multimodal analgesia (paracetamol + NSAIDs + local infiltration) — are implemented across all partner hospitals.

STEP 1 — REMOTE PRE-OPERATIVE EVALUATION (2–4 weeks before travel):

Upload existing medical records, imaging, and diagnostic reports to the GAF Healthcare patient portal. A urogynaecologist at the partner hospital reviews documents and issues a treatment plan, operative recommendation (native-tissue vs. mesh vs. robotic), and estimated costs within 48–72 hours. Any outstanding investigations (urodynamics, MRI) are scheduled at the destination hospital on arrival or, where possible, arranged locally before travel.

STEP 2 — ARRIVAL AND PRE-ADMISSION (Day 1–2):

GAF Healthcare airport transfer team receives the patient and companion. On Day 1 or 2, the patient attends the outpatient urogynaecology clinic for in-person POP-Q staging, review of urodynamic reports, vaginal assessment (including pessary removal if applicable), and surgical consent. Pre-operative blood tests, urine culture, ECG, and anaesthetic review are completed. Any untreated vaginal infection is managed with a 5–7 day antibiotic/antifungal course before rescheduling.

STEP 3 — ADMISSION AND SURGERY (Day 3):

Patient is admitted 4–6 hours pre-operatively. Standard bowel preparation (phosphate enema) may be administered. Intravenous antibiotic prophylaxis (cefazolin or co-amoxiclav) is given 30–60 minutes before incision per ACOG/RCOG guidelines. The operation (anterior colporrhaphy ± sling ± posterior repair) typically takes 45–90 minutes for native-tissue repair; robotic sacrocolpopexy takes 2–3 hours. Intraoperative cystoscopy with intravenous indigo carmine confirms bilateral ureteral efflux and bladder integrity before closure. A urethral catheter (Foley 14F) is left in situ.

STEP 4 — IMMEDIATE POST-OPERATIVE RECOVERY (Day 3 evening – Day 4):

Patient recovers in a monitored post-anaesthesia care unit (PACU) for 1–2 hours, then transfers to a private ward. Early ambulation is encouraged within 4–6 hours. Urethral catheter is maintained for 24–48 hours. ERAS analgesia protocol (scheduled paracetamol 1g QDS + ibuprofen 400mg TDS with meals, ± tramadol rescue) is implemented. Vaginal packing (if used) is removed at 12–24 hours.

STEP 5 — CATHETER TRIAL OF VOID AND DISCHARGE (Day 4–5):

Catheter is removed on post-operative Day 2. A trial of void is performed: the patient voids spontaneously, and post-void residual is measured by bedside bladder scan. PVR <150 mL on two consecutive voids = successful trial. If the trial fails (PVR >200 mL), intermittent self-catheterisation (ISC) is taught and a clean ISC programme is initiated. Discharge with written wound care instructions, pelvic floor physiotherapy referral, and activity restrictions.

STEP 6 — EARLY RECOVERY PHASE IN DESTINATION COUNTRY (Week 1–3):

Patient remains in accommodation arranged by GAF Healthcare near the hospital. Follow-up outpatient review at Day 7–10: wound inspection, PVR ultrasound, urine culture if symptomatic. Pelvic rest (no tampons, no sexual intercourse) for minimum 6 weeks. Activity restriction: no lifting >5 kg, no high-impact exercise, no prolonged standing for 6 weeks. Vaginal oestrogen cream (if post-menopausal) commenced at Week 2 to optimise tissue healing.

STEP 7 — FIT-TO-FLY ASSESSMENT (Week 3–4 for short-haul; Week 5–6 for long-haul):

Surgeon reviews clinical progress: absence of fever, no urinary retention, PVR <100 mL, wound epithelialised, no signs of haematoma or mesh exposure. Written fit-to-fly letter issued. DVT prophylaxis for the flight: low molecular weight heparin (LMWH, e.g., enoxaparin 40 mg SC) 2–4 hours pre-flight for high-risk patients, compression stockings, and in-flight hydration/ambulation advice.

STEP 8 — LONG-TERM RECOVERY MILESTONES (Home Country):

• Week 6: Pelvic rest lifted; sexual activity may resume after gynaecological clearance

• Week 6–8: Return to sedentary or desk-based work; driving when comfortable and not on opioids

• Month 3: Return to low-impact exercise (swimming, walking); pelvic floor physiotherapy ongoing

• Month 6: Full unrestricted activity; formal anatomical assessment (repeat POP-Q) at partner hospital or local gynaecologist

• Month 12–24: Long-term durability review; urodynamic re-assessment if new or residual symptoms